Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma

Journal of Neuro-Oncology

Volumn 44, Issue 2, 1999, Pages 137-145

  Gregor, A ^a   Lind, M ^b   Newman, H ^c   Grant, R ^a   Hadley, D M ^d   Barton, T ^e   Osborn, C ^e  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^d INSTITUTE OF NEUROLOGICAL SCIENCES   (United Kingdom)

^e Alkermes Europe Ltd   (United Kingdom)

Author keywords

Carboplatin; Glioma; RMP 7

Indexed keywords

ANTINEOPLASTIC AGENT; BRADYKININ DERIVATIVE; CARBOPLATIN; LOBRADIMIL;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; BLOOD TOXICITY; CANCER RECURRENCE; CLINICAL TRIAL; DEMYELINATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DYSGEUSIA; FOCAL EPILEPSY; GLIOMA; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERMEABILITY; PHASE 2 CLINICAL TRIAL; TUMOR VOLUME; VASODILATATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRADYKININ; BRAIN NEOPLASMS; CARBOPLATIN; GLIOMA; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 0032776321     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006379332212     Document Type: Article

References (24)

1. Bleehen NM, Stenning SP on behalf of the Medical Research Council Brain Tumour Working Party: A medical research council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. Brit J Cancer 64: 769-774, 1991
2. Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ, Wilson CB: Modified procarbazine, CCNU and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumours. Cancer Treatment Reports 64: 203, 1980
3. Fine HA: The basis for current treatment recommendations for malignant gliomas. J Neuro-Oncol 20: 111-120, 1994
4. Canetta R, Goodlow J, Smaldone L, Bragman K, Rozencweig M: Pharmacologic characteristics of carboplatin: clinical experience. In: Bunn PA Jr, Canetta R, Ozols RF, Rozencweig M (eds) Carboplatin (JM-8) Current Perspectives and Future Directions. WB Saunders Company, 1990, pp 19-37
5. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E: Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10: 520-528, 1992
6. Doz F, Berens ME, Dougherty DV, Rosenblum ML: Comparison of cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposures. J Neuro-Oncol 11: 27-35, 1991
7. Shinohara C, Matsumoto K, Meada Y, Tada E, Kuriyama M, Adachi H, Ono Y, Higashi H, Furata T, Ohmoto T: Synergistic effect of carboplatin and hyperthermia in rat and human glioma cell lines. Neurol Surg 22, 11: 1029-1033, 1994
8. Dodion P, Sanders C, Georges P, Kenis Y: In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin. Cancer Chemother Pharmacol 22: 80-82, 1988
9. Yung WK, Mechtler L, Gleason MJ: Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 9(5): 860-864, 1991
10. Warnick RE, Prados MD, Mack EE, Chandler KL, Doz F, Rabbitt JE, Malek MK: A phase II study of intravenous carboplatin for the treatment of recurrent glioma. J NeuroOncol 19(1): 69-74, 1994
11. Matsukado K, Inamura T, Nakano S, Fukui M, Bartus RT, Black KL: Enhanced tumour uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery 39(1): 125-134, 1997
12. Ford J, Osborn C, Barton T, Bleehen NM: Phase I Study of Intravenous RMP-7 with Carboplatin in Patients with Progression of Malignant Glioma. Eur J Cancer (in press)
13. Gehan EA: The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346-353, 1961
14. WHO publication No 48, WHO publications Centre USA, NY 12210, USA
15. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989
16. Hopper KD, Kasales CJ, Eggli KD, Belman NM, Potok PS, TenHave TR, Umlauf MJ, Van Slyke MA, Olt GJ, Close P, Lipton A, Harvey HA, Hartell JS, Go BDM: 2D versus 3D quantitation of tumour response to treatment. In: Quantitative Imaging in Oncology. Proceedings of the 19th LH Gray Conference. Faulkner K, Carey B, Crellin A and Harrison RM (eds). Pub British Institute of Radiology, London, 1996
17. Grant R, Slattery J, Gregor A, Whittle IR: Recording neurological impairment in clinical trials of glioma. J NeuroOncol 19: 37-49, 1994
18. Clyde Z, Chataway J, Grant R: The Edinburgh Functional Impairment Tests - detecting change in functional impairments in patients with cerebral glioma. Brit J Neurosurg 10(1): 124-125, 1996 (Abstract)
19. Grant R, Collie D: The effect of clinical presentation on management and outcome in patients with high grade glioma. J Neuro One 21: 20, 1994 (Abstract)
20. Clyde Z, Grant R: Simple objective tests of limb function and memory are valuable in assessing patients with brain tumors. Neurology A321: PO4.124, 1996 (Abstract)
21. Chataway SJS, Clyde Z, Signorini DF, Whittle IR, Grant R: What represents a clinically significant change in outcome measures following operation for brain tumour? J NeuroOncol, 1997 (submitted)
22. Yates JW, Chalmer B, McKegney FP: Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 45: 2220-2224, 1980
23. Macdonald DR, Cascino TL, Schold SC, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7): 1277-1280, 1990
24. Alvord EC: Patterns of growth of gliomas. American J Neuro Radiology 16: 1013-1017, 1995